Telehealth firms prescribe GLP-1s off-label for addiction ahead of FDA
Clinicians interviewed by STAT warn that fragmented prescribing exposes patients to unknown risks while addiction indications remain unapproved.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 22 04:30 ETSource: STAT
The wire
- 01STAT reports telehealth companies are marketing and prescribing GLP-1 drugs off-label for addiction, well ahead of any FDA-approved indication for that use.
- 02Prescribers and pharmacists fielding these requests face a use with no label support, and patients may receive the drugs outside coordinated addiction care.
- 03Experts quoted worry about fragmented care and unknown risks; formal trials of incretins in substance use disorders have not yet delivered approval-grade results.
From the source
Read at statnews.comSTAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
As telehealth promotes GLP-1s for addiction, experts worry about fragmented care, and exposing patients to unknown risks.
